CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 59 enrolled
Drug / intervention
alisertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00651664
NCT00651664Phase 1Completed
CompareCT.gov

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies

Millennium Pharmaceuticals, Inc.·interventional·Posted Apr 3, 2008·Updated Mar 15, 2019

In Brief

A Phase 1 clinical trial evaluating alisertib for Advanced Malignancies. Completed, enrolled 59 participants across 2 sites.

Detailed Summary

This is a multicenter, dose escalation, phase 1 study of MLN8237 in adult participants with advanced malignancies (excluding those with primary bone marrow involvement, such as leukemias and multiple myeloma).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignancies
CountriesSpain
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 3, 2008
Enrollment StartOct 22, 2007
Primary CompletionSep 1, 2010
Study CompletionApr 5, 2011
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 18.2 years ago

Interventions

alisertibdrug

Alisertib (MLN8237) capsules